Austar Lifesciences Ltd. AI Stock Analysis
Want to see HK:6118 full AI Analyst Report?
Austar Lifesciences Ltd. (6118) AI Stock Analysis
Austar Lifesciences Ltd.
(HKEX:6118)
Moderate score driven primarily by challenged financials with revenue declines and thin margins alongside weak technical momentum; reasonable P/E valuation offers limited support.
Austar Lifesciences Ltd. (6118) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 276.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 70.04K
- Price to Earnings (P/E)
- 13.2
- Beta (1Y)
- 0.81
- Revenue Growth
- 14.04%
- EPS Growth
- -49.19%
- Country
- Hong Kong
- Employees
- 1,468
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Austar Lifesciences Ltd. Business Overview & Revenue Model
Company Description
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland Chi...
How the Company Makes Money
Austar Lifesciences Ltd. generates revenue primarily by selling products and delivering services to customers in the life sciences and biopharmaceutical ecosystem. Key revenue streams typically include (1) distribution and sales of laboratory and bio...
Austar Lifesciences Ltd. Financial Statement Overview
Summary
Mixed results with declining revenue from 2.16B to 1.49B and thin margins offset by balance sheet stability and recent cash flow recovery to positive 128M operating cash flow.
Income Statement
45NeutralBalance Sheet
55NeutralCash Flow
50Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.60B | 1.53B | 1.50B | 1.76B | 2.16B | 2.02B |
| Gross Profit | 290.37M | 293.27M | 301.22M | 336.05M | 488.80M | 479.01M |
| EBITDA | 77.75M | 92.28M | 87.88M | 25.15M | 159.79M | 148.54M |
| Net Income | 17.15M | 33.80M | 16.08M | -113.47M | 87.46M | 277.30M |
Balance Sheet | ||||||
| Total Assets | 2.14B | 2.13B | 2.08B | 2.16B | 2.39B | 2.04B |
| Cash, Cash Equivalents and Short-Term Investments | 255.32M | 276.59M | 167.81M | 173.76M | 148.13M | 219.74M |
| Total Debt | 268.24M | 343.82M | 401.95M | 496.20M | 336.55M | 155.22M |
| Total Liabilities | 1.31B | 1.30B | 1.29B | 1.38B | 1.51B | 1.26B |
| Stockholders Equity | 831.23M | 822.90M | 791.41M | 773.01M | 896.94M | 786.58M |
Cash Flow | ||||||
| Free Cash Flow | 152.42M | 99.74M | 78.31M | -133.59M | -155.25M | -204.02M |
| Operating Cash Flow | 186.17M | 128.24M | 98.81M | -62.65M | -37.93M | -103.45M |
| Investing Cash Flow | -35.54M | -15.58M | 4.43M | -54.47M | -153.14M | 65.02M |
| Financing Cash Flow | -93.12M | -42.76M | -101.32M | 147.12M | 125.30M | 59.35M |
Austar Lifesciences Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6118, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.65, and below the 200-day MA of 0.74, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 34.04 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6118.
Austar Lifesciences Ltd. Peers Comparison
Overall Rating
HK:161271.1Outperform- HK:611850Neutral
HK:221649Neutral
HK:217045Neutral
HK:250044Neutral
HK:229740Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1612 | 71Outperform | HKD 448.87M | 4.57 | 13.95% | 6.76% | 10.95% | 9.26% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6118 | 50Neutral | HKD 279.36M | 13.20 | 2.07% | ― | 14.04% | -49.19% |
| HK:2216 | 49Neutral | HKD 296.09M | -1.87 | -12.45% | ― | ― | ― |
| HK:2170 | 45Neutral | HKD 366.52M | -1.81 | -19.34% | ― | -2.28% | 24.76% |
| HK:2500 | 44Neutral | HKD 449.83M | -0.80 | -28.24% | ― | -38.15% | 25.70% |
| HK:2297 | 40Underperform | HKD 229.82M | -2.52 | -19.46% | ― | 4.35% | 43.23% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6118 | Austar Lifesciences Ltd. | 0.52 | -0.48 | -48.00% | |
| HK:1612 | Vincent Medical Holdings Limited | 0.68 | -0.15 | -17.87% | |
| HK:2170 | Suzhou Basecare Medical Corp. Ltd. Class H | 1.36 | -1.01 | -42.65% | |
| HK:2216 | Broncus Holding Corp. | 0.55 | -2.14 | -79.55% | |
| HK:2297 | Rainmed Medical Limited | 0.14 | -0.14 | -50.00% | |
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 1.00 | -1.45 | -59.18% |
Austar Lifesciences Ltd. Corporate Events
Austar Lifesciences Grows Revenue but Interim Profit Slides on Margin Pressure
Austar Lifesciences reported unaudited interim results for the six months ended 30 June 2026 showing revenue rising to RMB744.5 million from RMB661.9 million a year earlier, but gross profit slipped slightly to RMB138.1 million as the margin narrowed...
Austar Lifesciences Sets Board Meeting to Review Interim Results and Dividend
Austar Lifesciences Limited has announced that its board of directors will meet on 25 August 2026 to review and approve the group’s unaudited interim results for the six months ended 30 June 2026. At the same meeting, the board will also consider whe...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026